GLS2 is protumorigenic in breast cancers (2020)
Source: Oncogene. Unidade: IFSC
Subjects: NEOPLASIAS MAMÁRIAS, GLUTAMINA, METÁSTASE NEOPLÁSICA
ABNT
DIAS, Marilia M. et al. GLS2 is protumorigenic in breast cancers. Oncogene, v. 39, n. Ja 2020, p. 690-720, 2020Tradução . . Disponível em: https://doi.org/10.1038/s41388-019-1007-z. Acesso em: 23 maio 2024.APA
Dias, M. M., Adamoski, D., Reis, L. M., Ascenção, C. F. R., Oliveira, K. R. S., Mafra, A. C. P., et al. (2020). GLS2 is protumorigenic in breast cancers. Oncogene, 39( Ja 2020), 690-720. doi:10.1038/s41388-019-1007-zNLM
Dias MM, Adamoski D, Reis LM, Ascenção CFR, Oliveira KRS, Mafra ACP, Bastos ACS, Quintero M, Cassago CG, Ferreira IM, Fidelis CHV, Rocco SA, Bajgelman MC, Stine Z, Berindan-Neagoe I, Calin GA, Ambrosio ALB, Dias SMG. GLS2 is protumorigenic in breast cancers [Internet]. Oncogene. 2020 ; 39( Ja 2020): 690-720.[citado 2024 maio 23 ] Available from: https://doi.org/10.1038/s41388-019-1007-zVancouver
Dias MM, Adamoski D, Reis LM, Ascenção CFR, Oliveira KRS, Mafra ACP, Bastos ACS, Quintero M, Cassago CG, Ferreira IM, Fidelis CHV, Rocco SA, Bajgelman MC, Stine Z, Berindan-Neagoe I, Calin GA, Ambrosio ALB, Dias SMG. GLS2 is protumorigenic in breast cancers [Internet]. Oncogene. 2020 ; 39( Ja 2020): 690-720.[citado 2024 maio 23 ] Available from: https://doi.org/10.1038/s41388-019-1007-z